卵巢癌分子病理检测临床实践指南

标题: 卵巢癌分子病理检测临床实践指南
title: clinical practice guideline on molecular pathology testing in ovarian cancer
版本: 原创版
version: Original
分类: 标准指南
classification: Standard guideline
领域: 诊疗
field: Diagnosis and Treatment
国家和地区: 中国
Country and region: China
指南使用者: 卵巢肿瘤专业医生
Guide users: ovarian oncologist and surgeon
证据分级方法: 证据等级分级体系参照GRADE体系结合临床研究结果制定。等级分为1类、2A类、2B类和3类,以量化编委会专家对证据可靠性的评价。1类:基于高级别临床研究证据,专家意见高度一致;基于低级别临床研究证据,专家意见高度一致;2A类:或基于高级别证据,专家意见基本一致;2B类:基于低级别临床研究证据,专家意见基本一致;3类:不论基于何种级别临床证据,专家意见明显分歧
Evidence grading method: The evidence level grading system was developed with reference to the GRADE system combined with clinical study results. The grades are divided into category 1, 2A, 2B and 3 to quantify the evaluation of the reliability of the evidence by the editorial committee experts. category 1: based on high-level clinical research evidence, experts' opinions are highly consistent; based on low-level clinical research evidence, experts' opinions are highly consistent; category 2A: or based on high-level evidence, experts' opinions are largely consistent; category 2B: based on low-level clinical research evidence, experts' opinions are largely consistent; category 3 : Clearly divergent expert opinions regardless of the level of clinical evidence.
制定单位: 中华医学会病理学分会;中华医学会妇科肿瘤学分会;国家病理质控中心
Formulating unit: Chinese society of pathology; Chinese society of gynecological oncology;National pathology quality control center
注册时间: 2022-06-24
Registration time:
注册编号: IPGRP-2022CN362
Registration number:
指南制订的目的: 推动卵巢癌精准诊疗的发展,规范化指导卵巢癌分子病理检测在临床实践中的应用,由中华医学会病理学分会,中华医学会妇科肿瘤学分会和国家病理质控中心三大学会牵头,组织国内分子病理学及临床的相关专家,基于国内外临床实践数据,结合中国国情,遵从中国制订/修订临床诊疗指南的指导原则(2022版),制订第一部《卵巢癌分子病理检测临床实践指南》,旨在系统性梳理卵巢癌分子病理检测的临床意义、检测方法,总结最佳的卵巢癌患者临床检测策略及路径,指导卵巢癌分子病理检测临床实践。
Purpose of the guideline: In order to promote the development of precise diagnosis and treatment of ovarian cancer and to standardize the application of molecular pathology testing for ovarian cancer in clinical practice, Chinese society of pathology, Chinese society of gynecological oncology and National pathology quality control center based on clinical practice data at home and abroad, combined with the national conditions of China, and complied with the guidelines for the development/revision of clinical guidelines for ovarian cancer in China (2022 edition). The aim is to systematically sort out the clinical significance and methods of molecular pathology testing for ovarian cancer, summarize the best clinical testing strategies and pathways for ovarian cancer patients, and guide the clinical practice of molecular pathology testing for ovarian cancer.